Climb Bio
CLYM
69 hedge funds and large institutions have $61.9M invested in Climb Bio in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 25 closing their positions.
2% less capital invested
Capital invested by funds: $63.4M → $61.9M (-$1.49M)
3.13% less ownership
Funds ownership: 76.97% → 73.83% (-3.1%)
8% less funds holding
Funds holding: 75 → 69 (-6)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$626K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$604K |
| 3 |
NFT
Nan Fung Trinity
Central, Hong Kong,
Hong Kong
|
+$577K |
| 4 |
Millennium Management
New York
|
+$519K |
| 5 |
SC
Shay Capital
New York
|
+$268K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.77M |
| 2 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$566K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$540K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$451K |
| 5 |
State Street
Boston,
Massachusetts
|
-$343K |
CLYM Hedge Fund Activity: Q2 2025 in Review
69 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q2 2025, worth a combined $61.9M — down 2.4% from $63.4M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CLYM and 19 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 19 added.
The largest buyer was Cantor Fitzgerald, adding an estimated $626K. The largest seller was BlackRock, cutting an estimated $1.77M.
- 69 institutional investors held Climb Bio (CLYM) as of Q2 2025, down from 75 in Q1 2025.
- Funds reported $61.9M of Climb Bio stock for Q2 2025, down 2.4% quarter-over-quarter.
- 19 funds opened new Climb Bio positions in Q2 2025 and 25 closed out, a net change of -6 holders.
- The largest Climb Bio buyer in Q2 2025 was Cantor Fitzgerald, an estimated $626K added.
- The largest Climb Bio seller in Q2 2025 was BlackRock, an estimated $1.77M sold.
Based on aggregated 13F filings for Q2 2025.